Crescent Biopharma (CBIO) Other Working Capital Changes (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Other Working Capital Changes data on file, last reported at -$101000.0 in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$101000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$263000.0 (up 48.88% YoY), and the FY2025 annual result was -$162000.0, up 78.15% from the prior year.
• Other Working Capital Changes improved to -$101000.0 in Q1 2026 per CBIO's latest filing, from -$222000.0 in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $240103.0 in Q1 2023 and troughed at -$762531.0 in Q2 2023.
• A 5-year average of -$188363.7 and a median of -$230847.0 in 2022 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes sank 538.98% in 2022, then surged 200.17% in 2023.
• A 5-year view of Other Working Capital Changes shows it stood at -$261549.0 in 2022, then surged by 74.58% to -$66486.0 in 2023, then tumbled by 673.82% to -$514480.0 in 2024, then surged by 56.85% to -$222000.0 in 2025, then soared by 54.5% to -$101000.0 in 2026.
• Business Quant data shows CBIO's Other Working Capital Changes at -$101000.0 in Q1 2026, -$222000.0 in Q4 2025, and $46000.0 in Q3 2025.